CHM and Parkinson disease: For example, polymorphisms in the SNCA promoter region, such as changes in the length of the dinucleotide repeat sequence REP1, were shown to affect α-synuclein levels in the blood and brain and, through this mechanism, could modulate PD risk and influence the severity of PD clinical manifestations [30, 31].